Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 3 Clinical Study to Determine the Pharmacokinetics, Safety and Efficacy of Recombinant Von Willebrand Factor : Recombinant Factor VIII (rVWF:rFVIII) and rVWF in the Treatment of Bleeding Episodes in Subjects Diagnosed With Von Willebrand Disease

NCT01410227 is registered in ClinicalTrials.gov with Baxalta now part of Shire as lead sponsor.

NCT NCT01410227
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01410227 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 3 Clinical Study to Determine the Pharmacokinetics, Safety and Efficacy of Recombinant Von Willebrand Factor : Recombinant Factor VIII (rVWF:rFVIII) and rVWF in the Treatment of Bleeding Episodes in Subjects Diagnosed With Von Willebrand Disease
Lead sponsor
Baxalta now part of Shire
Phase
Phase 3
Overall status
Completed
Start date
November 1, 2011
Completion date
February 1, 2014
Enrollment
49 (actual)
Sites
52

Conditions

As the registry lists them; a condition with its own page is linked.

von willebrand disease